1-8 of 8
Andrew Peng
Close
Sort by
Journal Articles

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Ran Reshef, Philip L. McCarthy, Nilanjan Ghosh, Aleksandr Lazaryan, Simone Filosto, Soumya Poddar, Daqin Mao, Andrew Peng, Adrian Kilcoyne, Myrna Nahas, Sattva S. Neelapu
Journal: Blood
Blood (2022) 140 (Supplement 1): 10318–10320.
https://doi.org/10.1182/blood-2022-167688
Published: 2022
Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 1595–1597.
https://doi.org/10.1182/blood-2022-158303
Published: 2022
Journal Articles

Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission

Gevorg Tamamyan, MD MSc, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Elias Jabbour, Naval Daver, MD, Naveen Pemmaraju, MD, Maro Ohanian, DO, Albert Kolomansky, MD, Gabriele Todisco, MD, Ce Shi, MD PhD, Sherry Pierce, BSN, BA, S. Andrew Peng, MS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan Kadia, MD
Journal: Blood
Blood (2015) 126 (23): 3850.
https://doi.org/10.1182/blood.V126.23.3850.3850
Published: 2015
Journal Articles

Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.

Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Amy Guo, PhD, James D. Griffin, MD, Andrew Peng Yu, PhD, Eric Qiong Wu, PhD
Journal: Blood
Blood (2010) 116 (21): 3437.
https://doi.org/10.1182/blood.V116.21.3437.3437
Published: 2010
Journal Articles

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Eric Qiong Wu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Denise Williams, MD, Amy Guo, PhD, Diego Ponce de Leon Barido, BA, BS, Andrew Peng Yu, PhD, Alfonso Quintás-Cardama, MD
Journal: Blood
Blood (2010) 116 (21): 3841.
https://doi.org/10.1182/blood.V116.21.3841.3841
Published: 2010
Journal Articles

Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia

Andrew Peng Yu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Martin Cloutier, Bsc, Denise Williams, MD
Journal: Blood
Blood (2010) 116 (21): 4758.
https://doi.org/10.1182/blood.V116.21.4758.4758
Published: 2010
Journal Articles

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Andrew Peng Yu, PhD, Arielle G Bensimon, BA, Maryna Marynchenko, MBA, Eric Qiong Wu, PhD, Madhav Namjoshi, PhD, Amy Guo, PhD, Solveig G Ericson, MD, PhD, Noopur Raje, MD
Journal: Blood
Blood (2010) 116 (21): 1956.
https://doi.org/10.1182/blood.V116.21.1956.1956
Published: 2010
Journal Articles

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Andrew Peng Yu, PhD, Andres Sirulnik, MD, PhD, James D Griffin, MD
Journal: Blood
Blood (2009) 114 (22): 4270.
https://doi.org/10.1182/blood.V114.22.4270.4270
Published: 2009